| Code | CSB-RA004888MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LY-3541860, targeting CD19, a transmembrane glycoprotein exclusively expressed on B cells throughout most stages of B-cell development. CD19 functions as a critical co-receptor in the B-cell receptor complex, modulating signal transduction thresholds and regulating B-cell activation, proliferation, and differentiation. As a pan-B-cell marker, CD19 plays a significant role in various B-cell malignancies including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphomas, making it an important target for immunotherapy research and biomarker studies.
LY-3541860 represents a therapeutic antibody designed for B-cell targeting applications in oncology research. This biosimilar antibody provides researchers with a reliable tool for investigating CD19-mediated signaling pathways, studying B-cell biology, and exploring immune-oncology mechanisms. It serves as a valuable reagent for preclinical studies examining B-cell depletion strategies and antibody-based therapeutic approaches in hematological malignancies.
There are currently no reviews for this product.